Monopar Therapeutics (MNPR) is presenting data from the clinical and preclinical development of its novel radiopharma program based on MNPR-101 at the European Association of Nuclear Medicine, EANM, 2024 Annual Congress held in Hamburg, Germany. MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. “We were able to optimize our uPAR-targeted radiopharmaceuticals in preclinical studies, and the data show these efforts have translated directly into humans with encouraging tumor uptake. Even at the highest Lu-177 therapeutic antibody dose we are aware of in the clinic, we estimate a favorable radiation dosimetry safety profile for off-target effects such as bone marrow exposure,” said Andrew Cittadine, Monopar’s Chief Operating Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Expands Portfolio with New Patent Filing
- Monopar files provisional patent covering therapeutic radiopharmaceuticals
- Monopar Therapeutics initiated with a Buy at Rodman & Renshaw
- Monopar Therapeutics initiates Phase 1a trial for MNPR-101-Lu
- Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial